Elizabeth Melton, APRN
Nurse Practitioner · Independence, MONPI 1902260144
Payments from drug & device makers
Across 159 payments — averaging $26.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$784
- Merck$518
- Johnson & Johnson$310
- AstraZeneca$253
- Seagen Inc.$224
- Takeda Pharmaceuticals U.S.A., Inc.$197
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,16099%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 14 | $784 |
| Merck | 22 | $518 |
| Johnson & Johnson | 14 | $310 |
| AstraZeneca | 8 | $253 |
| Seagen Inc. | 7 | $224 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $197 |
| Genmab U.S., Inc. | 4 | $175 |
| AbbVie | 3 | $175 |
| Ipsen Biopharmaceuticals, Inc | 8 | $174 |
| Genentech USA, Inc. | 9 | $165 |
| Incyte Corporation | 8 | $143 |
| Eisai Inc. | 8 | $142 |
| Sanofi | 6 | $125 |
| Daiichi Sankyo Inc. | 5 | $115 |
| Lilly USA, LLC | 4 | $70 |
| AVEO Pharmaceuticals, Inc. | 2 | $57 |
| Novartis | 3 | $54 |
| Immunogen, Inc. | 1 | $53 |
| Regeneron Healthcare Solutions, Inc. | 2 | $46 |
| Blueprint Medicines Corporation | 2 | $42 |
| Karyopharm Therapeutics Inc. | 2 | $40 |
| Puma Biotechnology, Inc. | 2 | $40 |
| Tersera Therapeutics LLC | 1 | $39 |
| Bristol Myers Squibb | 2 | $32 |
| Pharmaessentia USA Corporation | 2 | $28 |
| Boehringer Ingelheim | 1 | $26 |
| Mylan Institutional Inc. | 1 | $24 |
| Taiho Oncology, Inc. | 1 | $20 |
| Array Biopharma Inc | 1 | $18 |
| Bayer | 1 | $17 |
| G1 Therapeutics, Inc. | 1 | $17 |
| Biocon Biologics Inc | 1 | $16 |
| Stemline Therapeutics Inc. | 1 | $15 |
| Sobi, Inc | 1 | $15 |
| Novocure Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,182 in reported general payments places this provider in the 90th percentile of 1,898 nurse practitioner providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZejulaNiraparib Tosylate | 23 | $489,023 |
| LynparzaOlaparib | 24 | $200,797 |
| RubracaRucaparib Camsylate | 11 | $194,888 |
| Letrozole | 65 | $2,257 |
| Gabapentin | 96 | $2,044 |
| Megestrol Acetate | 19 | $912 |
| Duloxetine Hcl | 27 | $680 |
| Nifedipine ErNifedipine | 13 | $314 |
| Dexamethasone | 14 | $286 |
| Ondansetron OdtOndansetron | 14 | $239 |
| Prochlorperazine Maleate | 13 | $161 |
| Potassium Chloride | 15 | $76 |
| Amlodipine Besylate | 16 | $50 |
| Ondansetron Hcl | 11 | $28 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKZejula | $784 | $489,02323 claims |
| AstraZenecaLynparza | $253 | $200,79724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,898 nurse practitioner providers in Missouri.
Other nurse practitioner in Independence
- Laura BadamiIndependence$13K
- Vadsana SmithIndependence$12K
- Aeron SheffieldChesterfield$269K
- Rachel ImperatoOsage Beach$260K
- Matthew BrunsBridgeton$126K
- Michelle DickensSpringfield$59K
- Robert HafnerKansas City$47K
- Tracey CarpenterChesterfield$47K
- Laura GrantSaint Charles$34K
- Courtney JefferyKansas City$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.